Reading Time: 4 minutes This is blog number 21 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). At present, the only…
Reading Time: 4 minutes This is blog number 20 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Clinical trials are research…
Reading Time: 5 minutes This is blog number 19 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Clinical trials are research…
Reading Time: 4 minutes This is blog number 18 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). As we learn more…
Reading Time: 4 minutes This is blog number 17 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Drug discovery can be…
Reading Time: 4 minutes This is blog number 15 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). There is currently no…
Reading Time: 7 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…
Reading Time: 6 minutes Each year, MND Associations across the globe mark 21 June as a special day of recognition, acknowledging the impact that MND has on people around the world. MND is a global problem. It does not discriminate, and for every person diagnosed the effects of the disease will be forever felt by their families and friends.…
Reading Time: 4 minutes While the exact cause of MND remains unknown, two of the hallmarks of the disease are a build-up, or aggregation, of toxic proteins in motor neurons and the misfolding of proteins. Protein folding is the physical process by which a protein chain becomes biologically functional. If it doesn’t fold properly, it can’t function properly. These…
Reading Time: 3 minutes This is the first in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different speakers about how the COVID-19 pandemic has impacted their own experiences of clinical trials, research, and support within the MND community. A further blog, written by Bruce Virgo who is…
